![Christopher Kroeger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Kroeger
Fondateur chez
MAPLIGHT THERAPEUTICS, INC.
Fortune : 44 M $ au 31/05/2026
Profil
Christopher A. Kroeger is the founder of MapLight Therapeutics, Inc., founded in 2018, where the titles held are President, Chief Executive Officer & Director.
Current jobs include Director at Antlia Bioscience, Inc. and Director at Stellaromics, Inc. Former jobs include President, Chief Executive Officer & Director at Cardioxyl Pharmaceuticals LLC from 2012 to 2016; President, Chief Executive Officer & Director at OvaScience, Inc. from 2017 to 2018; Chief Executive Officer at Millendo Therapeutics, Inc.; Director at Neotropix, Inc.; Director at HyperBranch Medical Technology, Inc.; Director at Cantex Pharmaceuticals, Inc.; Director at CardioFocus, Inc.; Principal at Biogen, Inc.; Principal at Genzyme Corp.; Analyst at Arthur D.
Little, Inc.; and Principal at The Aurora Funds, Inc. from 2003 to 2007.
Education includes undergraduate degree from Harvard University, doctorate from Stanford University School of Medicine, and MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/05/2026 | 1 495 284 ( 3,51 % ) | 44 M $ | 31/05/2026 |
Postes actifs de Christopher Kroeger
| Sociétés | Poste | Début |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Fondateur | 01/11/2018 |
Antlia Bioscience, Inc.
 Antlia Bioscience, Inc. BiotechnologyHealth Technology Manufactures ground-breaking peptide-based therapies | Directeur/Membre du Conseil | - |
Anciens postes connus de Christopher Kroeger
| Sociétés | Poste | Fin |
|---|---|---|
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Directeur Général | 07/12/2018 |
Cardioxyl Pharmaceuticals LLC
 Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Discovers and develops therapies and technologies for the treatment of cardiovascular diseases | Directeur Général | 01/04/2016 |
Cantex Pharmaceuticals, Inc.
 Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops heparin to ameliorate cardiac ischemia-reperfusion injuries | Directeur/Membre du Conseil | - |
Neotropix, Inc.
 Neotropix, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes virus-based therapies for cancer treatment | Directeur/Membre du Conseil | - |
CardioFocus, Inc.
 CardioFocus, Inc. Medical SpecialtiesHealth Technology Develops and markets catheter-based technologies to treating atrial fibrillation | Directeur/Membre du Conseil | - |
Formation de Christopher Kroeger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
16
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Neotropix, Inc.
Neotropix, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes virus-based therapies for cancer treatment | Commercial Services |
HyperBranch Medical Technology, Inc.
 HyperBranch Medical Technology, Inc. Medical SpecialtiesHealth Technology Develops and markets biosurgical devices | Health Technology |
Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops heparin to ameliorate cardiac ischemia-reperfusion injuries | Health Technology |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Discovers and develops therapies and technologies for the treatment of cardiovascular diseases | Health Technology |
Arthur D. Little, Inc.
 Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Aurora Funds, Inc.
 The Aurora Funds, Inc. Investment ManagersFinance Aurora Funds invests in companies located in the United States. The firm targets companies operating in the fields of healthcare and information technology. It provides financing for early stage capital requirements. | Finance |
CardioFocus, Inc.
CardioFocus, Inc. Medical SpecialtiesHealth Technology Develops and markets catheter-based technologies to treating atrial fibrillation | Health Technology |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Health Technology |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
MapLight Therapeutics, Inc.
 MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Antlia Bioscience, Inc.
Antlia Bioscience, Inc. BiotechnologyHealth Technology Manufactures ground-breaking peptide-based therapies | Health Technology |
Choisissez Zonebourse 
